Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas P Restifo

Showing results (131-140 of 260) with videos related to

Pageof 26
Sort By:
Blood|February 16, 2008
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapyChristian S Hinrichs, Rosanne Spolski, Chrystal M Paulos, et al.
Stem Cell Research & Therapy|December 18, 2020
Correction to: Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiationSelami Demirci, Juan J Haro-Mora, Alexis Leonard, et al.
The Journal of Experimental Medicine|December 31, 2020
STING agonist promotes CAR T cell trafficking and persistence in breast cancerNuo Xu, Douglas C Palmer, Alexander C Robeson, et al.
The Journal of Biological Chemistry|September 9, 2011
Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivoYanan Liu, Xiaoli Tian, Wolfgang W Leitner, et al.
Cancer Immunology, Immunotherapy : CII|February 18, 2011
Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in miceSally M Amos, Hollie J Pegram, Jennifer A Westwood, et al.
Journal for Immunotherapy of Cancer|February 18, 2016
Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioningMichelle H Nelson, Jacob S Bowers, Stefanie R Bailey, et al.
The Journal of Clinical Investigation|November 19, 2010
Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunitySung P Ha, Nicholas D Klemen, Garrett H Kinnebrew, et al.
Cancer Immunology, Immunotherapy : CII|October 20, 2019
Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiationAnthony L Schwartz, Pulak R Nath, Michael Allgauer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2003
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigensRichard A Morgan, Mark E Dudley, Yik Y L Yu, et al.
The Journal of Experimental Medicine|February 17, 2010
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsSergio A Quezada, Tyler R Simpson, Karl S Peggs, et al.
Pageof 26

Showing results (131-140 of 260) with videos related to

Sort By:
Pageof 26
Blood|February 16, 2008
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapyChristian S Hinrichs, Rosanne Spolski, Chrystal M Paulos, et al.
Stem Cell Research & Therapy|December 18, 2020
Correction to: Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiationSelami Demirci, Juan J Haro-Mora, Alexis Leonard, et al.
The Journal of Experimental Medicine|December 31, 2020
STING agonist promotes CAR T cell trafficking and persistence in breast cancerNuo Xu, Douglas C Palmer, Alexander C Robeson, et al.
The Journal of Biological Chemistry|September 9, 2011
Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivoYanan Liu, Xiaoli Tian, Wolfgang W Leitner, et al.
Cancer Immunology, Immunotherapy : CII|February 18, 2011
Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in miceSally M Amos, Hollie J Pegram, Jennifer A Westwood, et al.
Journal for Immunotherapy of Cancer|February 18, 2016
Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioningMichelle H Nelson, Jacob S Bowers, Stefanie R Bailey, et al.
The Journal of Clinical Investigation|November 19, 2010
Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunitySung P Ha, Nicholas D Klemen, Garrett H Kinnebrew, et al.
Cancer Immunology, Immunotherapy : CII|October 20, 2019
Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiationAnthony L Schwartz, Pulak R Nath, Michael Allgauer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2003
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigensRichard A Morgan, Mark E Dudley, Yik Y L Yu, et al.
The Journal of Experimental Medicine|February 17, 2010
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsSergio A Quezada, Tyler R Simpson, Karl S Peggs, et al.
Pageof 26